Caplin Point Lab
Drug Manufacturers - Specialty & Generic · CAPLIPOINT
Mid CapHealthcareHigh Growth
Sridhar Ganesan
Managing Director · Visionary
Company DNA
Performance-Driven
About
Caplin Point Lab is a Mid Cap company in the Healthcare sector, listed on NSE as CAPLIPOINT. With a market cap of ₹13K Cr and revenue of ₹2K Cr, it is currently in the High Growth phase. Known for its Performance-Driven culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. Rapidly growing specialty pharma player with a focus on cost-efficient manufacturing and market penetration metrics. Its strategic mandate: Rapid international expansion into emerging markets requires a focus on scalable distribution networks and regulatory compliance.
FAQ
What kind of company is Caplin Point Lab?
Caplin Point Lab is a Mid Cap Healthcare company (CAPLIPOINT) in the High Growth phase with a market cap of ₹13K Cr. It is classified as Performance-Driven in culture.
What is Caplin Point Lab's culture and work environment like?
Caplin Point Lab has a Performance-Driven culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Rapidly growing specialty pharma player with a focus on cost-efficient manufacturing and market penetration metrics.
Who leads Caplin Point Lab?
Caplin Point Lab is led by Sridhar Ganesan (Managing Director), a Visionary leader with 30 years of experience.
What are Caplin Point Lab's financials?
Caplin Point Lab reported revenue of ₹2K Cr in FY25 with a 5-year revenue CAGR of 15.1%. Operating margin: 30%. Market cap: ₹13K Cr.
Culture & Strategy
CulturePerformance-Driven
InnovationFast-Follower
PaceStartup-Speed
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandValue-Champion
LifecycleHigh Growth
Rapidly growing specialty pharma player with a focus on cost-efficient manufacturing and market penetration metrics.
Mandate
Rapid international expansion into emerging markets requires a focus on scalable distribution networks and regulatory compliance.
Rapid international expansion into emerging markets requires a focus on scalable distribution networks and regulatory compliance.
Financials
Revenue FY25₹2K Cr
PAT FY25₹536 Cr
Rev CAGR 5Y15.1%
OPM30%
NPM27.7%
ROE18.8%
ROCE20%
P/E20.7
Fwd P/E18.1
P/B4.1
D/E0.2
Mkt Cap₹13K Cr
Promoter73.7%
Institutional5.4%
Similar Culture
Could You Lead Caplin Point Lab?
Take the Genome Benchmark →